BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther 2017;17:879-86. [PMID: 28472597 DOI: 10.1080/14712598.2017.1327576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Risto A, Abdalla M, Myrelid P. Staging Pouch Surgery in Ulcerative Colitis in the Biological Era. Clin Colon Rectal Surg 2022;35:058-65. [DOI: 10.1055/s-0041-1740039] [Reference Citation Analysis]
2 Lubrano E, Luchetti MM, Benfaremo D, Mauro D, Ciccia F, Perrotta FM. Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. Expert Rev Clin Immunol 2021;17:1199-209. [PMID: 34622735 DOI: 10.1080/1744666X.2021.1991315] [Reference Citation Analysis]
3 Romeo AC, Ventimiglia M, Dipasquale V, Orlando A, Citrano M, Pellegrino S, Accomando S, Cottone M, Romano C. Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. Clinics and Research in Hepatology and Gastroenterology 2020;44:223-9. [DOI: 10.1016/j.clinre.2019.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 [PMID: 33178391 DOI: 10.4252/wjsc.v12.i10.1050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis). BMJ Open Gastroenterol 2018;5:e000212. [PMID: 30002864 DOI: 10.1136/bmjgast-2018-000212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
6 Retnakumar SV, Muller S. Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases. Trends Mol Med 2019;25:516-37. [PMID: 30952481 DOI: 10.1016/j.molmed.2019.03.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
7 Ibáñez Vodnizza SE, De La Fuente MPP, Parra Cancino EC. Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease. Rheum Dis Clin North Am 2020;46:275-86. [PMID: 32340701 DOI: 10.1016/j.rdc.2020.01.004] [Reference Citation Analysis]
8 Chevalier R. siRNA Targeting and Treatment of Gastrointestinal Diseases. Clin Transl Sci 2019;12:573-85. [PMID: 31309709 DOI: 10.1111/cts.12668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cordeiro N, Freitas RHCN, Fraga CAM, Fernandes PD. Therapeutic Effects of Anti-Inflammatory N-Acylhydrazones in the Resolution of Experimental Colitis. J Pharmacol Exp Ther 2020;374:420-7. [PMID: 32546529 DOI: 10.1124/jpet.120.000074] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
11 Niu W, Chen X, Xu R, Dong H, Yang F, Wang Y, Zhang Z, Ju J. Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review. Carbohydr Polym 2021;254:117189. [PMID: 33357839 DOI: 10.1016/j.carbpol.2020.117189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
12 Huldani H, Margiana R, Ahmad F, Opulencia MJC, Ansari MJ, Bokov DO, Abdullaeva NN, Siahmansouri H. Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells. International Immunopharmacology 2022;107:108698. [DOI: 10.1016/j.intimp.2022.108698] [Reference Citation Analysis]
13 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
14 Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): where we stand today. Hum Vaccin Immunother 2021;17:1586-98. [PMID: 33369527 DOI: 10.1080/21645515.2020.1836919] [Reference Citation Analysis]
15 Melendez-Gonzalez MDM, Hamad J, Sayed C. Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure. J Invest Dermatol 2021;141:2975-9. [PMID: 34097922 DOI: 10.1016/j.jid.2021.04.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Roy A, Geetha RV, Magesh A, Vijayaraghavan R, Ravichandran V. Autoinjector - A smart device for emergency cum personal therapy. Saudi Pharm J 2021;29:1205-15. [PMID: 34703373 DOI: 10.1016/j.jsps.2021.09.004] [Reference Citation Analysis]
17 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]